Speeda Mechanism of Action

Pharmacotherapeutic Group: Anti-rabies. Rabies Vaccine for Human Use. ATC Code: J07BG01.
Pharmacology: Pharmacodynamics: Mechanism of Action: The vaccine contains inactivated rabies virus, which stimulates the immune system to produce antibodies that protect against rabies. The virus is grown in Vero cells, then harvested, concentrated, inactivated, purified, and freeze-dried. Once administered, the vaccine induces a protective immune response by encouraging the production of antibodies that neutralize the rabies virus.
Clinical Efficacy and Safety: The vaccine is produced under strict quality controls by Liaoning Cheng Da Biotechnology Co., Ltd. It is administered intramuscularly or intradermally to provide sufficient immune protection. After reconstitution, the vaccine should be immediately used.
Pharmacokinetics: Pharmacokinetic studies are generally not required for vaccines, as they primarily function to trigger an immune response rather than undergo typical absorption, distribution, metabolism, and excretion (ADME) processes like other drugs. The inactivated rabies virus in the vaccine is recognized by the immune system, which produces antibodies without significant distribution or metabolism within the body. Therefore, the pharmacokinetics of this vaccine are not applicable according to WHO guidelines on nonclinical evaluation of vaccines.